On February 4, Gilead reported 2018 results, with total revenue of 221.$2.7 billion, down 15% from 2017.2%.Among them, AIDS products sales income 146. 5%.$2.7 billion, an increase of 12 compared to 2017.4%, the share of the company's total revenue has recovered to 66.1%, the company's core business sector.In 2018, Gilead R & D investment 50.1.8 billion US dollars, accounting for 22.7% compared to 2017 34.4%.
$8.4 billion, by AbbVie's 36.$1.6 billion, a small overshoot.Generation star Sovaldi has fallen into a position where product sales are no longer specifically disclosed (combined revenue with Cayston, Hepsera 3.$200 million), close to exiting the stage.It's not just Gilead that is lonely. BMS's hepatitis C product was eliminated in 2018.
The good point is that Gilead has a good news in China in 2018. Harvoni was approved to treat the gene type 1-6 hepatitis C. Epclusa was approved and entered the "2018 version of the National Essential Drugs List" published in November 2018. The hepatitis B new drug Vemlid has very A good increase was also approved in November 2018. The listing of these products in China can help Gilead hedge the decline in the global liver disease business.
Gilead's brighter new product is the CAR-T therapy Yescarta, which offers treatment options for patients with relapsed and refractory large B-cell lymphoma who have received more than 2 treatments, winning 2.With $6.4 billion in revenue, it's much better than Novartis's Kymriah ($ 76 million).
2019 may be a year in which Gilead's new CEO will lead the company to accelerate its transformation. Daniel O'Day from Roche will officially perform his duties on March 1, 2019.After gaining a foothold in the field of CAR-T, Gilead has increased its further layout of the field of oncology, previously associated with Agenus.Tango Therapeutics has reached a deal that could lead to more outside action in 2019, after all, as of December 31, 2018, Gilead has $31.5 billion in cash assets (including cash equivalents and valuable debt securities) on its books.